Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$450.97 USD
+0.60 (0.13%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $450.72 -0.25 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
VRTX 450.97 +0.60(0.13%)
Will VRTX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRTX
MCK Stock Down Despite Latest Partnership to Boost SCD Treatment
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
GILD or VRTX: Which Is the Better Value Stock Right Now?
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Other News for VRTX
January 2025 Options Now Available For Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals (VRTX) Receives a Hold from Scotiabank
Vertex Pharmaceuticals: Promising Growth with Suzetrigine Potential and Strategic Diversification
Vertex Pharmaceuticals (VRTX) Receives a Hold from Stifel Nicolaus
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)